Skin tumorigenesis results from DNA damage, increased inflammation, and evasion of apoptosis. The peroxisome proliferator-activated receptors (PPARs) can modulate these mechanisms in non-melanoma skin cancer. However, limited data exists regarding the role of PPARs in melanoma. This study examined the effect of proliferator- Results from these studies demonstrate the antitumorigenic effects of both PPARb/d and PPARc and suggest that targeting these receptors may be useful for primary or secondary melanoma chemoprevention.
Melanoma is the sixth leading cause of cancer in the United States, and it is estimated that 87 000 people will be diagnosed with this disease in 2017 (Siegel et al. 2017) . The prognosis and 5-year survival rate is very good for patients with localized melanomas (98.2%), but the 5-year survival rates precipitously decrease for regional (62.4%) and malignant (17.9%) melanoma (Howlader et al., 2016; Siegel et al., 2017) . Based on the 5-year survival rate, malignant melanoma is more deadly than breast, ovarian, or prostate cancer (Siegel et al., 2017) .
Melanoma originates from malignant proliferation of genetically altered melanocytes. Large-scale next-generation sequencing has identified several molecular signatures linked with the ontology of melanoma. For example, the mitogenactivated protein kinase and phosphatidylinositol 3 kinase/protein kinase B (AKT) pathways are frequently mutated, amplified, or deleted in malignant melanoma (reviewed in Kunz, 2014; Shtivelman et al., 2014; Zhang et al., 2016) . Further, a number of related genes exhibit oncogenic mutations including BRAF (50% of tumors), NRAS (20%-25% of tumors), ERBB4 (15%-20% of tumors), AKT3 (25% of tumors), and PTEN (40%-60% of tumors) in melanomas (reviewed in Kunz, 2014; Shtivelman et al., 2014; Zhang et al., 2016) . These genetic alterations modulate activity in these pathways that result in increased cell proliferation, increased cell survival, cell migration, and angiogenesis. Therapies targeting some of these pathways has led to significant improvement in the treatment of malignant melanoma, including the use of BRAF inhibitors and/or immunotherapies (reviewed in Franklin et al., 2016; Shtivelman et al., 2014) . Despite the progress in therapeutically treating malignant melanoma, alternative strategies based on novel discoveries mediating the etiology and signaling pathways associated with this disease remains of high significance.
Peroxisome proliferator-activated receptor-b/d (PPARb/d) and PPARc are ligand-activated transcription factors that modulate numerous biological processes by several unique mechanisms. PPARb/d and PPARc mediate dynamic changes in gene expression by association with specific chromatin binding sites, which is influenced by multiple factors including the presence of endogenous/exogenous ligands, expression and activity of chromatin remodeling proteins, co-repressors, co-activators, and other intracellular proteins (Biddie et al., 2010; Hager and Varticovski, 2012) . The PPARs can also regulate gene expression through protein-protein interactions. The most classic example is the interaction between PPARs and the p65 subunit of NF-kB causing down-regulation of proinflammatory signaling (reviewed in Peters et al., 2012 Peters et al., , 2015a . Combined, PPARs can modulate many biological effects by both direct transcription regulation of target genes and by indirect protein-protein interactions. Overall, the PPARs modulate many essential biological processes in the body, including lipid and glucose homeostasis, terminal differentiation, and inflammation (reviewed in Peters et al., 2012) .
The role of PPARb/d in carcinogenesis remains controversial; while it is well accepted that activation of PPARc inhibits or can be targeted for treating cancer (reviewed in Peters and Gonzalez, 2009; Peters et al., 2012 Peters et al., , 2015a . Interestingly, PPARb/d is expressed at relatively high levels in melanocytes and melanoma cells (Eastham et al., 2008; Kang et al., 2004) ; suggesting that PPARb/d modulates melanocyte activity and function. Moreover, there is some evidence that relatively high expression of PPARb/d may interfere with ligand-dependent PPARc activities (Shi et al., 2002; Wang et al., 2012) . Thus, the present study examined the effect of PPARb/d or PPARc in the human melanoma cancer cell line UACC903 using both in vitro and in vivo models.
MATERIALS AND METHODS
Materials and cell culture. [4-[[[2-[3-fluoro-4-(trifluoromethyl) phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy acetic acid (GW0742) was synthesized by GlaxoSmithKline (Research Triangle Park, North Carolina). Rosiglitazone maleate was purchased from Santa Cruz Biotechnologies (Santa Cruz, Californina). Both PPAR ligands were dissolved in dimethylsulfoxide (DMSO). Primers for quantitative real-time polymerase chain reaction (qPCR) were purchased from Integrated DNA Technologies (Coralville, Iowa). The UACC903 melanoma cell line with the V600E-BRAF mutation was provided by Mark Nelson (University of Arizona, Tucson, Arizona). The UACC903 melanoma cell line was examined as a representative human melanoma cell line because it contains the BRAF V600E mutation and a deletion of PTEN, genotypes found in approximately 50% of all melanoma patients, which is considerably higher than other mutations in human melanoma (reviewed in Kunz, 2014; Shtivelman et al., 2014; Zhang et al., 2016) . UACC903 cells were cultured in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin solution at 37 C and 5% carbon dioxide, and used within a narrow passage range. The UACC903 cells were also annually monitored for genotypic characteristics, phenotypic behavior and tumorigenic potential to confirm identity. Athymic NCr-nu/nu mice were purchased from the National Cancer Institute (NCI, Frederick, Maryland).
Generation of stable UACC903 cell lines overexpressing PPARb/d or PPARc. Stable human UACC903 malignant melanoma cell lines overexpressing PPARb/d or PPARc were generated using the Migr1 bicistronic retrovirus vector (Pear et al., 1998) . The Migr1 vector has a mouse stem cell promoter that drives expression of enhanced green fluorescent protein (eGFP), in addition to an internal ribosome entry site allowing for cloning different cDNAs of interest. This type of vector that yields relatively high expression of PPARs has been described previously in Borland et al., (2011 ), Foreman et al. (2011 ), Yao et al. (2014 , 2015 (Heinaniemi et al., 2007) or adipocyte differentiation-related protein (ADRP), and the putative PPARb/d target gene 3-phosphoinositide-dependent protein kinase 1 (PDPK1) (Di-Poi et al., 2002) as previously described . Each assay included a standard curve with greater than 85% efficiency and a no-template control. The relative mRNA expression of PPARb/d, PPARc, ADRP, ANGPTL4, and PDPK1 was normalized to the relative mRNA value for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Western blot analysis. Soluble protein lysates were isolated from 90% to 95% confluent 100 mm culture dishes as previously described in Borland et al. (2011) . Fifty micrograms of protein per sample was separated using SDS-polyacrylamide gels and transferred to a PVDF membrane using an electroblotting method. The membranes were blocked with 5% dried milk in Flow cytometric analysis of cell cycle progression. The UACC903 cells were seeded onto 6-well tissue culture dishes at a concentration of 250 000 cells per well and cultured in DMEM with 10% FBS and 1% penicillin/streptomycin for 24 h. After this initial 24 h culture period without additional treatment, flow cytometric analysis was performed as described below. Additionally, in separate cohorts of cells, 24 h postplating, cells were cultured in medium with or without GW0742 (0.0, 0.01, 0.1, 1.0, or 10.0 mM) or rosiglitazone (0.0, 0.01, 0.1, 1.0, or 10.0 mM) for 24 h. After these treatments, culture medium was removed and the cells were trypsinized, pelleted and fixed in ice cold 70% ethanol. Prior to analysis, cells were stained with propidium iodide (PI) solution containing 1 mg PI/ml and 0.125% RNase A (Sigma Aldrich, St. Louis, Missouri). Approximately 10 000 cells/sample were analyzed using an EPICS-XL-MCL flow cytometer (Beckman Coulter, Miami Lakes, Florida) fitted with a single 15-mW argon ion laser providing excitation at 488 nm. The percentage of cells at each phase of the cell cycle was determined with MultiCycle analysis software. Values were calculated from a minimum of 3 independent samples per treatment.
Effect of ligand activation and overexpression of PPARb/d or PPARc on cell proliferation. UACC903 cells were plated on a 12-well plate at a density of 25 000 cells/well 24 h before cell counting at time 0.
Cell proliferation was determined using a Z1 Coulter particle counter (Beckman Coulter, Hialeah, Florida) . After the first 24 h, cells were cultured in DMEM containing the vehicle control (0.02%DMSO), GW0742 (0.01-10.0 lM), or rosiglitazone (0.01-10.0 lM). Cells were counted every 24-72 h postligand treatment. Triplicate samples for each treatment were used for each time point, and each replicate was counted 3 times. Cell population doubling time was calculated from the 24-to 72-h time point to prevent log phase growth bias. Doubling time for each replicate was calculated as follows: Ectopic xenografts. Ectopic xenografts were induced in athymic nude mice as previously described in Yao et al. (2014) . Briefly, 6-week-old female immune-deficient athymic nude (nu/nu) mice were injected subcutaneously with 1 Â 10 6 cells per hind flank. The UACC903-Migr1 cells were injected in the left rear flank and the UACC903-hPPARb/d cells were injected in the right rear flank. Alternatively, the UACC903-Migr1 cells were injected in the left rear flank and the UACC903-hPPARc cells were injected in the right rear flank. Groups of mice were then treated with or without GW0742 (2.5 mg/kg/d) or rosiglitazone (10 mg/kg/d) for up to 36 days. The PPAR ligands were provided by daily dosing with a pellet made with Bacon-flavored Transgenic Dough Diet (Bioserv, Inc., Flemington, New Jersey) mixed with either vehicle control (0.02% DMSO), GW0742 or rosiglitazone. Body weight and tumor volumes were measured 3 times a week. Mice were euthanized by overexposure to carbon dioxide, and tumors were carefully dissected. Half of each tumor was fixed in 10% phosphate buffered formalin, and the other half was snap frozen in liquid nitrogen for subsequent analysis of proteins by western blot analysis or mRNA expression by qPCR as described above. Fixed tumor sections were processed for staining as previously described (Yao et al., 2015) . Hematoxylin-eosin (H&E) stained tumor sections were examined by a pathologist. A terminal deoxy-nucleotidyl transferasemediated digoxigenin-dUTP nick end labeling (TUNEL) assay was performed to detect apoptotic fragmentation of DNA in paraffin-embedded tumor sections using the ApopTag kit (Chemicon, Temecula, California) following the manufacturer's instructions. Twenty fields per section and 2 sections per tumor sample were analyzed. The relative level of apoptosis was determined by normalizing the intensity of 3,3 0 -diaminobenzidine to hematoxylin signals using ImageJ software (Version 1.47c).
Data analysis. Data were analyzed for statistical significance using one-way analysis of variance (ANOVA) and the Bonferroni's multiple comparison tests, or Student's t-test using Prism 5.0 (GraphPad Software Inc., La Jolla, California). All data are presented as the mean 6 SEM. Figure 1D ). Although ligand activation of PPARb/d by GW0742 increased the expression of the target gene ANGPTL4 in all 4 cell lines, the induction was markedly higher in UACC903 cells overexpressing PPARb/d ( Figure 1E ). Ligand activation of PPARb/d did not influence expression of the putative PPARb/d target PDPK1 in any of the cell lines as compared with controls ( Figure 1F ). Similarly, ligand activation of PPARc caused markedly enhanced expression of ANGPTL4 mRNA in UACC903 cells overexpressing PPARc as compared with controls ( Figure 1G ) while expression of PDPK1 mRNA was unchanged following ligand activation of PPARc by rosiglitazone ( Figure 1H ).
RESULTS

Enhanced PPAR Activity in UACC903 Human
Overexpression of PPARs and Ligand Activation of PPARs Modulates Cell Cycle Kinetics and Proliferation of UACC903 Human Melanoma Cells
Twenty-four hours after plating the 4 different cell lines, overexpression of either PPARb/d or PPARc resulted in a decrease in the percentage of cells in both the G1 and S phase, and an increase in the percentage of cells in the G2/M phase as compared with control UACC903 or UACC903-Migr1 cells (Figure 2A ). It is also worth noting that the percentage of cells within each phase of the cell cycle was not different between the control UACC903 and control UACC903-Migr1 cell lines (Figure 2A ). Although changes in G1, S and G2/M phases as described above were noted in the UACC903-hPPARb/d cells as compared with controls, ligand activation of PPARb/d did not further alter cell cycle kinetics in any of the 4 UACC903 cell lines ( Figure 2B ). By contrast, although the changes in G1, S, and G2/M phases as described above were observed in the UACC903-hPPARc cells, ligand activation of PPARc dose-dependently increased the percentage of cells in the G1 phase and decreased the percentage of cells within both the S and G2/M phase in UACC903-hPPARc cells, and this effect was not found in control UACC903, UACC903-Migr1, or UACC903-hPPARb/d cells ( Figure 2C ). Given that both PPARb/d and PPARc modulated cell cycle kinetics, the ability of both receptors to modulate cell proliferation in the presence or absence of ligand activation was examined using cell counting over a 72-h period. Ligand activation of PPARb/d with GW0742 reduced cell proliferation in cells overexpressing PPARb/d; these effects were observed as early as 48 h posttreatment ( Figure 3E ). Although ligand activation of PPARb/d had no effect on cell proliferation in UACC903-Migr1, or UACC903-hPPARc cells (Figs. 3A, C, and G) , proliferation of control UACC903 cells was inhibited by ligand activation of PPARb/d by GW0742 (10.0 mM) after 72 h ( Figure 3A) . Similarly, ligand activation of PPARc by rosiglitazone markedly reduced cell proliferation in cells overexpressing PPARc within 48 h ( Figure 3H ). Ligand activation of PPARc by rosiglitazone did not alter proliferation in control UACC903 cells, UACC903-Migr1 cells, or UACC903-hPPARb/d cells (Figs. 3B, D, and F) . Interestingly, human melanoma cancer cells overexpressing PPARb/d never achieved cell confluency equivalent to the other cell lines. The doubling time for the control UACC903, UACC903-Migr1, and UACC903-hPPARc cell lines were all similar at approximately 21 h; however, cells overexpressing PPARb/d required more time, approximately 24 h, to double in population ( Figure 3I ). Ligand activation of PPARc by rosiglitazone caused a 33% reduction in the colony surviving fraction ( Figure 4D ). Although the reduction was only observed in cells overexpressing PPARc, a strong dose-dependent effect was observed in this cell line ( Figure 4D ).
Ligand Activation and/or Overexpression of PPARb/d and PPARc Inhibit Ectopic Xenografts
Ligand activation of PPARb/d by GW0742 markedly inhibited tumor volume, tumor weight, and tumor area in ectopic xenografts derived from UACC903-Migr1 cells as compared with controls (Figs. 5A-F) . A similar phenotype was also observed in ectopic xenografts derived from UACC903-hPPARb/d cells as that observed with ligand activation of PPARb/d in ectopic xenografts derived from UACC903-Migr1 cells (Figs. 5A-F) . The effects observed in ectopic xenografts derived from UACC903-hPPARb/d cells, with or without ligand activation of PPARb/d were similar to tumors derived from UACC903-Migr1 cells in response to ligand activation of PPARb/d (Figs. 5A-F) . The latter suggests the presence of an endogenous ligand and is consistent with the observed increase in relative expression of the PPARb/d target gene ADRP in ectopic xenografts derived from UACC903-hPPARb/d cells as compared with controls ( Figure 5C ). Histological examination of the tumor tissues revealed infiltrating neutrophils within the tumor area and the infiltration was notably reduced in tumors in response to ligand activation of PPARb/d ( Figure 5E ). Although overexpression PPARb/d alone did not alter apoptotic index compared with tumors derived from UACC903-Migr1 cells, ligand activation of PPARb/d increased apoptosis in tumors derived from UACC903-hPPARb/d cells as compared with controls ( Figure 5G ).
Ligand activation of PPARc by rosiglitazone markedly inhibited tumor volume, tumor weight, and tumor area in ectopic xenografts derived from UACC903-Migr1 cells as compared with controls (Figs. 6A-F) . A similar phenotype was also observed in ectopic xenografts derived from UACC903-hPPARc cells as that observed with ligand activation of PPARc in ectopic xenografts derived from UACC903-Migr1 cells (Figs. 6A-F) . The effects observed in ectopic xenografts derived from UACC903-hPPARc cells, with or without ligand activation of PPARc were similar to tumors derived from UACC903-Migr1 cells in response to ligand activation of PPARc (Figs. 6A-F) . The latter suggests the presence of an endogenous ligand and is consistent with the observed increase in relative expression of the PPARc target gene ADRP in ectopic xenografts derived from UACC903-hPPARc cells as compared with controls ( Figure 6C ). These effects were comparable to tumors derived from UACC903-Migr1 cells in response to ligand activation of PPARc (Figs. 5A-E) . Histological examination of the tumor tissues revealed infiltrating neutrophils within the tumor area and the infiltration was inhibited in tumors in response to ligand activation of PPARc ( Figure 6E ). Overexpression of PPARc alone increased the apoptotic index compared with tumors derived from UACC903-Migr1 cells, whereas ligand activation of PPARc by rosiglitazone did not further increase the apoptotic index in tumors derived from UACC903-hPPARc cells as compared with controls ( Figure 6G ).
DISCUSSION
Results from the present studies are substantive for many reasons. The role of PPARb/d remains controversial because there are conflicting studies, with some showing that activation of PPARb/d promotes tumorigenesis and others showing that ligand activation of PPARb/d inhibits tumorigenesis (Peters et al., , 2015a . Thus, more rigorous studies are needed to more precisely determine the role of PPARb/d in carcinogenesis so that this nodal transcription factor can be targeted for cancer chemoprevention and/or chemotherapy. To date, there are limited studies that have examined the role of PPARb/d in melanoma.
The first study that reported a role for PPARb/d in melanoma demonstrated that ligand activation PPARb/d with either GW501516 or GW0742 inhibited proliferation of human UACC903 melanoma cells as compared with controls . A second study examined the role of PPARb/d in a human (A375) or a mouse (B16F0) melanoma cell line and also observed that ligand activation PPARb/d with either GW501516 or GW0742 inhibited proliferation, but this change was not due to increased apoptosis (Michiels et al., 2010) . Results from the present studies are consistent with these 2 studies as they demonstrate that ligand activation and/or overexpression of PPARb/ d inhibits tumorigenesis in a human melanoma cancer cell line. Moreover, these studies extend the former studies with complementary in vitro and in vivo analysis, and most importantly, demonstrate that ligand activation PPARb/d inhibits ectopic xenografts derived from a human melanoma cancer cell line with one of the most common mutations found in this disease. The mechanism underlying this preventive effect is likely mediated in part by the induction of apoptosis and a block in the G2/M phase of the cell cycle, consistent with previous studies (Borland et al., 2008 Zhu et al., 2012) . It is unclear why the studies by Michiels and colleagues did not detect changes in apoptosis following ligand activation PPARb/d in human A375 melanoma cells compared with controls. It remains possible that this could be due to differences present in the in vitro analysis versus the in vivo analysis, or to differences in the sensitivities between A375 cells versus UACC903 melanoma cell lines. Further studies are needed to distinguish between these possibilities. It is also worth noting that the present studies also provide additional data showing that ligand activation and/or overexpression of PPARb/d does not increase expression of PDPK1, which is consistent with other studies (Ahmed et al., 2008; Borland et al., 2008 Borland et al., , 2011 Zhu et al., 2014) , but in contrast to another report (Di-Poi et al., 2002) . The reason for this difference cannot be determined from these studies but the weight of evidence that PDPK1 is not a target gene of PPARb/d is becoming stronger.
Results from these studies also demonstrated that overexpression and/or ligand activation of PPARc inhibits a human melanoma cancer cell line proliferation and this effect is reflected by the observed inhibition of ectopic xenograft tumorigenicity and enhanced apoptosis as compared with controls. In contrast to the effect of ligand activation of PPARb/d in carcinogenesis, the effect of the role of PPARc in cancer is relatively less contentious. Results from these studies show that ligand activation and/or overexpression of PPARc inhibits UACC903 cell cycle progression, proliferation and ectopic xenografts as compared with controls. These results are consistent with numerous studies showing similar effects in melanoma cancer cell lines (Botton et al., 2009; Chen et al., 2014; Eastham et al., 2008; Freudlsperger et al., 2006 Freudlsperger et al., , 2007 Freudlsperger et al., , 2008 Klopper et al., 2009 Klopper et al., , 2010 Meyer et al., 2010; Mossner et al., 2002; Nunez et al., 2006; Papi et al., 2009; Paulitschke et al., 2012; Placha et al., 2003; Sertznig et al., 2008 Sertznig et al., , 2009 . Of particular interest is the study showing that increased expression of ANGPTL4 prevents migration and invasion of melanoma cells (Galaup et al., 2006) , as this target gene is increased by both ligand activation and/or overexpression of either PPARb/d or PPARc.
The relative expression of PPARb/d in cancer cells as compared with control untransformed tissue is another area of contention. It has become increasingly clear that relative expression of PPARb/d is lower in most, but not all, tumor cells as compared with untransformed tissue (reviewed in (Peters et al., , 2015a . In contrast to the original suggestion that PPARb/d mRNA expression is higher in colon tumors as compared with control tissue (He et al., 1999) , it has been shown that expression of PPARb/d protein is markedly lower in most human and mouse colon tumors as compared with controls (Foreman et al., 2011; reviewed in Peters et al., 2012 reviewed in Peters et al., , 2015a . The hypothesis that relative expression of PPARb/d is higher in most tumors as compared with control tissue has been disputed for years and led to an alternative hypothesis that relatively high expression of PPARb/d in cancer cells could interfere with PPARc signaling (Wang et al., 2012) . Since it is known that ligand activation of PPARc inhibits carcinogenesis by inducing differentiation and apoptosis, this was of interest because relatively high expression of PPARb/d in cancer cells as compared with untransformed tissue, this could interfere with the chemopreventive effects mediated by ligand activation of PPARc. In addition to the fact that there are large databases showing that relative expression of PPARb/d protein is markedly lower in most human and mouse colon tumors as compared with controls (reviewed in Peters et al., 2012 Peters et al., , 2015a , results from the present studies provide new evidence to address the hypothesis that relatively high expression of PPARb/d in cancer cells could prevent the chemopreventive activities associated with ligand activation of PPARc. For example, relatively high expression of PPARb/d did not influence the relative efficacy of rosiglitazone to activate PPARc in UACC903 cells as compared with controls, as shown by the relative increase ANGPTL4 expression. Further, relatively high expression of PPARb/d did not influence the relative ability of the PPARc ligand rosiglitazone to modulate cell cycle or cell proliferation as compared with controls in UACC903 cells. Combined, these additional new data provide striking new evidence that increased expression of PPARb/d in a human melanoma cancer cell line can not only be beneficial because it can inhibit tumorigenesis as assessed both in vitro and in vivo, but they also strongly argue against the hypothesis that relatively high expression of PPARb/d in cancer cells could interfere with PPARc signaling as suggested by others (Wang et al., 2012) .
The results from the present studies and those by Girroir and Michiels examining melanoma cancer cell lines are in contrast to the original observation reported by others suggesting that overexpression of PPARb/d promotes tumorigenesis in human colon cancer (He et al., 1999) . Interestingly, at least 5 published studies describing the effects of overexpression of PPARb/ d in human cancer cell lines indicate that relatively higher expression of PPARb/d inhibits, but does not promote, proliferation of human cancer cell lines Foreman et al., 2011; Yao et al., 2014 Yao et al., , 2015 Yao et al., , 2017 . This is of interest to note because recent studies attempting to replicate results from studies examining druggable cancer targets demonstrated that the reported results are not consistently reproducible (Errington et al., 2014) . This is important to note because the effect of ligand activation of PPARb/d in 2 A375 variant human melanoma cell lines (A375P and A375SM; the former with lower metastatic potential, the latter with greater metastatic potential) suggested that ligand activation PPARb/d promoted migration and invasion of human A375SM melanoma cells but did not influence migration or invasion in human A375P melanoma cells as compared with controls (Ham et al. 2014) . The reason(s) for the differences between the present studies and others Michiels et al., 2010) , and the study suggesting that ligand activation PPARb/d promotes melanoma migration and invasion cannot be determined from the present studies. However, these disparate results illustrate the need for future, more rigorous studies. This will provide for stronger rationales for the targeting of either PPARb/d or PPARc for melanoma chemoprevention and/or chemotherapy.
